These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30517711)

  • 1. Age May Influence the Impact of TRAbs on Thyroid Function and Relapse-Risk in Patients With Graves Disease.
    Bano A; Gan E; Addison C; Narayanan K; Weaver JU; Tsatlidis V; Razvi S
    J Clin Endocrinol Metab; 2019 May; 104(5):1378-1385. PubMed ID: 30517711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age Moderates the Impact of TRAbs on Thyroid Hormones and Hepatic Function in Patients with Graves' Disease.
    Guo K; Ling H; Zhou X; Ying C
    Horm Metab Res; 2021 Jul; 53(7):453-460. PubMed ID: 34282596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble CD40 Ligand Levels in Children with Newly Diagnosed Graves’ Disease.
    Metwalley KA; Farghaly HS; Raafat DM; Ismail AM; Saied GM
    J Clin Res Pediatr Endocrinol; 2020 Jun; 12(2):197-201. PubMed ID: 31782290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
    Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Bucci I; Carpentieri M; Di Nenno B; Di Blasio A; Vitti P; Monaco F; Napolitano G
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
    Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
    Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulating and blocking thyroid-stimulating hormone (TSH) receptor autoantibodies from patients with Graves' disease and autoimmune hypothyroidism have very similar concentration, TSH receptor affinity, and binding sites.
    Morgenthaler NG; Ho SC; Minich WB
    J Clin Endocrinol Metab; 2007 Mar; 92(3):1058-65. PubMed ID: 17179194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of TSH-receptor antibodies in patients with toxic multinodular goitre by radioiodine treatment.
    Wallaschofski H; Müller D; Georgi P; Paschke R
    Horm Metab Res; 2002 Jan; 34(1):36-9. PubMed ID: 11833000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Five TSH-Receptor Antibody Assays in Graves' disease: results from an observational pilot study.
    Struja T; Jutzi R; Imahorn N; Kaeslin M; Boesiger F; Kutz A; Mundwiler E; Huber A; Kraenzlin M; Mueller B; Meier C; Bernasconi L; Schuetz P
    BMC Endocr Disord; 2019 Apr; 19(1):38. PubMed ID: 31023276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age moderates the associations between TRAbs, free T3 and outcomes of Graves' disease patients with radioactive iodine treatment.
    Lu L; Gao C; Zhang N
    Clin Endocrinol (Oxf); 2021 Feb; 94(2):303-309. PubMed ID: 32734611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved prediction of relapse of Graves' thyrotoxicosis by combined determination of TSH receptor and thyroperoxidase antibodies.
    Schott M; Eckstein A; Willenberg HS; Nguyen TB; Morgenthaler NG; Scherbaum WA
    Horm Metab Res; 2007 Jan; 39(1):56-61. PubMed ID: 17226115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.
    Schott M; Minich WB; Willenberg HS; Papewalis C; Seissler J; Feldkamp J; Bergmann A; Scherbaum WA; Morgenthaler NG
    Horm Metab Res; 2005 Dec; 37(12):741-4. PubMed ID: 16372227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves' Disease Relapse.
    Tun NN; Beckett G; Zammitt NN; Strachan MW; Seckl JR; Gibb FW
    Thyroid; 2016 Aug; 26(8):1004-9. PubMed ID: 27266892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) Gene, Thyroid Stimulating Hormone Receptor (TSHR) Gene and Regulatory T-cells as Risk Factors for Relapse in Patients with Graves Disease.
    Eliana F; Suwondo P; Asmarinah A; Harahap A; Djauzi S; Prihartono J; Pemayun TGD
    Acta Med Indones; 2017 Jul; 49(3):195-204. PubMed ID: 29093229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum 25-hydroxyvitamin D might be an independent prognostic factor for Graves disease recurrence.
    Ahn HY; Chung YJ; Cho BY
    Medicine (Baltimore); 2017 Aug; 96(31):e7700. PubMed ID: 28767604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The negative correlation between thyrotropin receptor-stimulating antibodies and bone mineral density in postmenopausal patients with Graves' disease.
    Amashukeli M; Korinteli M; Zerekidze T; Jikurauli N; Shanava S; Tsagareli M; Giorgadze E
    J Investig Med; 2013 Jun; 61(5):842-7. PubMed ID: 23612147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves' disease treated using antithyroid medication.
    Smith J; Brown RS
    Thyroid; 2007 Nov; 17(11):1103-7. PubMed ID: 17822376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulating TSH receptor autoantibodies immunoassay: analytical evaluation and clinical performance in Graves' disease.
    Autilio C; Morelli R; Locantore P; Pontecorvi A; Zuppi C; Carrozza C
    Ann Clin Biochem; 2018 Jan; 55(1):172-177. PubMed ID: 28388869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid blood flow as a useful predictor of relapse of Graves' disease after normal delivery in patients with Graves' disease.
    Nagasaki T; Inaba M; Fujiwara-Ueda M; Nishio J; Kumeda Y; Hiura Y; Tahara H; Ishimura E; Ishiko O; Nishizawa Y
    Biomed Pharmacother; 2010 Feb; 64(2):113-7. PubMed ID: 20006462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid hypoechogenicity after methimazole withdrawal in Graves' disease: a useful index for predicting recurrence?
    Zingrillo M; D'Aloiso L; Ghiggi MR; Di Cerbo A; Chiodini I; Torlontano M; Liuzzi A
    Clin Endocrinol (Oxf); 1996 Aug; 45(2):201-6. PubMed ID: 8881453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.